DiscoveryProbe™ FDA-approved Drug Library: Mechanisms, Benchmarks, and HTS Applications

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) contains 2,320 compounds verified as clinically approved by agencies such as the FDA, EMA, HMA, CFDA, and PMDA, supporting both high-throughput and high-content screening applications (APExBIO). The library includes drugs with diverse mechanisms, such as receptor agonists/antagonists, enzyme inhibitors, and ion channel modulators. Peer-reviewed studies have validated the utility of FDA-approved libraries for identifying novel inhibitors and repositioning drugs against multidrug-resistant pathogens (Qiu et al., 2024). The DiscoveryProbe™ collection is available pre-dissolved at 10 mM in DMSO, delivered in various user-friendly formats, ensuring reproducibility and ease of integration into existing platforms. This resource accelerates pharmacological target identification and supports translational workflows in fields from oncology to neurodegenerative disease research.

Biological Rationale

The rapid emergence of multidrug-resistant pathogens and the limited pipeline of novel therapeutics have driven a resurgence in drug repositioning and mechanism-based screening strategies (Qiu et al., 2024). Libraries of clinically approved drugs, such as the DiscoveryProbe™ FDA-approved Drug Library, are essential for efficient identification of compounds with well-characterized safety profiles and pharmacokinetics. Their utility spans the discovery of new indications for established drugs, validation of novel therapeutic targets, and deconvolution of cellular pathways in disease models. The breadth of pharmacological classes present—ranging from small-molecule kinase inhibitors to metabolic modulators—enables systematic interrogation of biological processes and facilitates translation from bench to bedside. The inclusion of only compounds with regulatory or pharmacopeial approval ensures that findings are immediately relevant to clinical contexts, bypassing early-stage toxicity and ADME hurdles (DiscoveryProbe Structured Review).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library covers a comprehensive spectrum of mechanisms, including:

• Receptor agonists and antagonists: e.g., β-adrenergic blockers, opioid receptor agonists.
• Enzyme inhibitors: e.g., statins (HMG-CoA reductase inhibitors), kinase inhibitors, protease inhibitors.
• Ion channel modulators: e.g., calcium channel blockers.
• Signal pathway regulators: e.g., mTOR inhibitors, MAPK pathway modulators.

Representative compounds include doxorubicin (topoisomerase inhibitor), metformin (AMPK activator), and atorvastatin (lipid-lowering agent), each with established clinical mechanisms. The diversity supports both hypothesis-driven and phenotypic screening modalities, crucial for drug repositioning and target validation (Transformative Screening Workflows). For example, in the context of antibiotic resistance, researchers have repurposed FDA-approved agents, such as dexrazoxane and candesartan cilexetil, as potent inhibitors of metallo-β-lactamases, restoring carbapenem efficacy in resistant bacterial strains (Qiu et al., 2024).

Evidence & Benchmarks

• Screening of FDA-approved drug libraries identified twelve compounds that inhibited New Delhi metallo-β-lactamase-1 (NDM-1) activity in vitro, with four demonstrating pan-metallo-β-lactamase inhibition and clinical synergy with meropenem (Qiu et al., 2024).
• The DiscoveryProbe™ collection provides 2,320 compounds in 10 mM DMSO, stable for up to 24 months at -80°C, ensuring long-term reproducibility in high-throughput workflows (APExBIO).
• High-throughput screening (HTS) with this library achieved robust Z'-factor values (>0.7) in cell viability and cytotoxicity assays across multiple platforms (Optimizing Cell-Based Assays).
• Drug repositioning screens using clinically approved libraries have accelerated the identification of new indications for cancer, neurodegenerative diseases, and rare genetic disorders (Applications in Oncology and CNS).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is engineered for broad application in academic and industry research, including:

• Drug Repositioning Screening: Rapid identification of alternative therapeutic uses for known drugs.
• Pharmacological Target Identification: Mechanistic deconvolution in cellular models.
• Cancer Research Drug Screening: Validation of candidate compounds in tumor cell lines and patient-derived xenografts.
• Neurodegenerative Disease Drug Discovery: Screening for neuroprotective or disease-modifying agents.
• Signal Pathway Regulation Studies: Deciphering complex signaling networks and feedback mechanisms.
• Enzyme Inhibitor Screening: Identification of compounds inhibiting clinically relevant enzymes, such as β-lactamases.

This article extends the discussion in DiscoveryProbe™ FDA-approved Drug Library: Structured Review by providing mechanism-specific evidence and practical limitations, and clarifies integration best practices compared to Optimizing Cell-Based Assays, which focuses on assay-specific optimizations.

Common Pitfalls or Misconceptions

• Not all clinical drugs are represented: Only compounds with regulatory or pharmacopeial approval are included; investigational or withdrawn drugs are absent.
• Single-dose limitation: Stock solutions are provided at 10 mM; users must perform serial dilutions for dose-response curves.
• Solubility in DMSO: Some hydrophobic drugs may precipitate if not equilibrated to room temperature before use.
• Not suitable for in vivo administration as supplied: DMSO vehicle and concentration are optimized for in vitro screening, not direct animal dosing.
• Mechanism assignment is context-dependent: Some drugs have multiple targets or pleiotropic effects, which may vary by cell type or assay.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is supplied as ready-to-use 10 mM DMSO solutions in 96-well microplates, deep well plates, or 2D barcoded screw-top tubes. Storage at -20°C ensures 12 months of stability; at -80°C, up to 24 months. Shipping is performed on blue ice for evaluation samples and at room temperature or blue ice by request for other sizes (APExBIO). For high-throughput screening, plates are compatible with automated liquid handlers and robotic systems. Typical screening concentrations range from 1 to 20 µM, with DMSO kept below 0.1% v/v in assay wells to minimize vehicle effects. Integration with cell-based and biochemical assays is seamless, with robust performance in Z'-factor validation and low inter-plate variability (Accelerating HTS).

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library, curated by APExBIO, is a validated platform for mechanism-driven screening, drug repositioning, and pharmacological research. Its regulatory-grade curation, solution stability, and diverse mechanistic coverage accelerate the identification of novel targets and translational candidates. Future applications will likely expand with integration into AI-driven drug discovery and phenotypic screening platforms, enabling more efficient translation from molecular insight to clinical intervention.

For full details and ordering information, visit the official DiscoveryProbe™ FDA-approved Drug Library product page.